AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05494190 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant chemoradiotherapy
Description: Radiotherapy: using intensity-modulated radiation therapy (IMRT)~Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0\~2.2 Gy per day, 5 days per week~Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65\~70 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Prophylactic irradiation for sites of suspected subclinical spread: 50\~60 Gy in total, 1.7\~2.0 Gy per day, 5 days per week~Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks.
Study NCT05494190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Neck dissection and primary tumor resection
Study NCT05494190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Neck dissection and primary tumor resection
Study NCT05826314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boxing training
Description: Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
Study NCT05826314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Training protocol will be held for 24 weeks, twice per week/ 45 min per sessions.
Study NCT05271240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation
Description: Subjects who are assigned to the IA BV+TMZ/RT group (Treatment Group), in addition to your standard of care cancer treatment, you will have a dose of bevacizumab delivered directly to your brain through superselective intra-cranial intra-arterial catheterization of the arteries that supply blood to your brain tumor along with the start of the initial 42 day oral temozolomide treatment. IA BV will be repeated every three months for a total of 3 infusions.
Study NCT05271240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide and Radiation Alone
Description: Subjects who are assigned to the TMZ/RT alone group (Control Group) you will receive standard of care cancer treatment that involves a daily oral dose of temozolomide for 42 days with radiation to the tumor followed by 28 days of rest and then repeated maintenance treatment cycles of daily oral temozolomide 5 days on and 23 days off.
Study NCT05913232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 0.6%
Description: ophthalmic solution
Study NCT05913232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 1.0%
Description: ophthalmic solution
Study NCT05913232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 Placebo
Description: ophthalmic solution
Study NCT05913232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol 0.5%
Description: ophthalmic solution
Study NCT05227196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 1
Description: Tablet given orally
Study NCT05227196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 2
Description: Tablet given orally
Study NCT05227196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D Dose 3
Description: Tablet given orally
Study NCT05227196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 4
Description: Tablet given orally
Study NCT05227196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 5
Description: Tablet given orally
Study NCT05227196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Dose 6
Description: Tablet given orally
Study NCT04907357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Each rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC).
Study NCT04907357 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (Placebo)
Description: Each sham rTMS session will consist of 75 rTMS trains of 10 Hz for 4 seconds (40 pulses per train) with inter-train interval (ITI) of 11 seconds (a total of 3000 stimuli per session) over the left dorsolateral prefrontal cortex (DLPFC). In the placebo condition the magnetic field will be delivered in the opposite direction (away from the brain).
Study NCT05506657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Center Facilitator-Coordinated Services
Description: A facilitator affiliated with Kessler Institute for Rehabilitation coordinates services that consider the participant's condition, needs and goals. Services participants may receive include:~* Education on programs designed to help people with spinal cord injury or brain injury pursue employment.~* Advice and guidance from professional counselors who have special training in helping people with disabilities pursue employment.~* Help completing applications for services.~* Assistance communicating with my employer about my needs and ways to accommodate them.~* Referrals to and services from other health care or technology providers.
Study NCT06117605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse SIRS alert
Description: An electronic alert will display when a nurse opens the patient chart of a patient who meets SIRS criteria.
Study NCT05909995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB 99280 with Ipilimumab
Description: Dose Escalation and expansion of INCB 99280 with Ipilimumab
Study NCT06117605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescribing clinician SIRS alert
Description: An electronic alert will display when a prescribing clinician opens the patient chart of a patient who meets SIRS criteria.
Study NCT06133179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transtemporal ultrasound with contrast product (Sonovue)
Description: During their hospitalization and in the 7 days following their stroke, all patients will perform a transtemporal ultrasound including the use of Sonovue contrast product.~The examination will last 1 hour and will be carried out on the opposite side of the stroke then on the side of the stroke
Study NCT06521125 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High resolution Computed Tomography (HRCT) scans of the Chest
Description: A chest high-resolution computed tomography (HRCT) scan will be performed
Study NCT06521125 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Testing (PFTs)
Description: Spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) measurements will be performed
Study NCT06521125 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Digital lung sounds auscultation
Description: Lung sounds will be recorded using a manual approach with a digital stethoscope
Study NCT06521125 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Assessments
Description: Clinical laboratory tests will be collected from each participant
Study NCT06521125 — intervention group
Intervention type: GENETIC
Intervention: DNA sequencing
Description: A sample of genomic DNA from peripheral blood lymphocytes will be collected for DNA sequencing
Study NCT06204757 — intervention group
Intervention type: OTHER
Intervention: questionary
Description: questionary relating to birth trauma are completed by midwives and patients
Study NCT04327154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TISSIUM™ Nerve Coaptation Device
Description: Placement of the TISSIUM™ Nerve Coaptation Device on repair site to achieve an end-to-end nerve coaptation.
Study NCT06061809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive 10mg/kg of Bevacizumab intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
Study NCT06061809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: Participants will receive PD-L1 t-haNK (\~2 × 109 cells/infusion) intravenously (IV) on Day 1 and Day 15 of each repeated cycle of treatment.
Study NCT06061809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: Participants will receive 1mg subcutaneously (SC) on Day 1 and Day 15 of each repeated cycle of treatment.
Study NCT04673643 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution.
Study NCT04673643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution. Patients in control group were applied using the same stimulator, stimulation parameters and same sessions. However, the electrodes were placed on the antihelix around the affected ear, which is the region of few vagus nerve branch distribution.
Study NCT04673643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid eye drops
Description: Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
Study NCT04673643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid eye drops
Description: Participants in both groups received hyaluronic acid eye drops (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany) with the treatment of 3 times a day.
Study NCT05222451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA Diet
Description: A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans (DGA)~Including:~* A variety of vegetables and fruits~* Grains, at least half of which are whole grains~* Fat-free or low-fat dairy~* A variety of protein foods, including seafood, lean meats and poultry, eggs, legumes, nuts, and seeds~* This healthy eating pattern also limits saturated fats and trans fats, added sugars, and sodium.
Study NCT05222451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MCT Diet
Description: A fully provisioned isocaloric, isonitrogenous study diet following the Dietary Guidelines for Americans supplemented with medium chain triglycerides (MCT).
Study NCT05222451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KETO Diet
Description: A fully provisioned isocaloric, isonitrogenous ketogenic study diet.
Study NCT05961722 — intervention group
Intervention type: OTHER
Intervention: preoperative IV 0.9% saline 400 ml
Description: Group 1 will be infused with IV 0.9% saline 400 mL.
Study NCT05961722 — intervention group
Intervention type: OTHER
Intervention: preoperative dextrose 5% 400 ml
Description: Group 2 will be infused with dextrose 5% Dekstroz 400 ml.
Study NCT05961722 — intervention group
Intervention type: OTHER
Intervention: preoperative and intraoperative dextrose 5% 400 ml
Description: Group 3 will be infused with dextrose preoperative 200 ml and intraoperative 200 ml 5% dextrose infusion.
Study NCT02809235 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coconut oil
Description: 3 tablespoons per day of supplemental coconut oil
Study NCT05562999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium Bromide
Description: Moderate NMB (TOF 1-2)
Study NCT05562999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: Deep NMB (PTC 1-2)
Study NCT05205031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraosseous access
Description: Needle placed in the bone marrow.
Study NCT05205031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous
Description: Needle placed in a vein.
Study NCT03708900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: osilodrostat (LCI699) is in the form of tablets for oral administration and comes in the following tablet strengths: 1 milligram (mg), 5 mg, and 10mg.
Study NCT06119048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Phenylalanine
Description: 100 mg/kg
Study NCT06655168 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Video Laryngoscopy
Description: orotracheal intubation by C-Mac ( Video laryngoscopy)
Study NCT06655168 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Direct Laryngoscopy
Description: Orotracheal intubation using Direct Laryngoscopy
Study NCT06503874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention Training
Description: The APT-3 is an evidence-based, standardized computer-based training program that was designed to improve attention skills that underlie higher level cognitive processes (e.g., executive functions and memory).
Study NCT06503874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Group
Description: This group will listen to a pre-determined playlist of music following the same dosing as the attention training group as stated in the arms.
Study NCT06602713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Western Ontario Shoulder Instability questionnaire Western Ontario Rotator Cuff questionnaire Shoulder Instability Return to Sport after Injury questionnaire
Study NCT06602713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Western Ontario Shoulder Instability questionnaire Western Ontario Rotator Cuff questionnaire Shoulder Instability Return to Sport after Injury questionnaire
Study NCT06602713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercices
Description: isokinetic evaluation
Study NCT06602713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercices
Description: isokinetic evaluation
Study NCT06594250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal swab
Description: Nasal swab to detect nasal carriage of S. aureus
Study NCT06594250 — intervention group
Intervention type: BIOLOGICAL
Intervention: Venous sampling
Description: Peripheral venous sampling to collect peripheral blood mononuclear cells.
Study NCT06594250 — intervention group
Intervention type: BIOLOGICAL
Intervention: Antibiotic treatment
Description: Antibiotic treatment for bacteremia (+/- 1 month), in all patients with S. aureus
Study NCT06594250 — intervention group
Intervention type: DEVICE
Intervention: Nasal swab
Description: A new nasal swab will be taken using the same technique, to see whether or not the carriage persists
Study NCT06594250 — intervention group
Intervention type: BIOLOGICAL
Intervention: Intracellular reservoir test
Description: In the event of positive carriage, a new intracellular reservoir test will be performed. A search for relapse (new S. aureus infection) or recurrence (S. aureus bacteremia if the 1st bacteremia was due to another pathogen) will be carried out.
Study NCT06593223 — intervention group
Intervention type: DEVICE
Intervention: Assess Non-invasive filling pressure(NIFP) in heart failure patients
Description: Assess Non-invasive filling pressure(NIFP) in outpatients with stable heart failure and inpatients with acute heart failure in ward
Study NCT06597110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: listened to ASMR
Description: ASMR refers to a physiological sensation triggered by specific auditory stimuli.ASMR, characterized by low-frequency human voice and ambient sounds, has garnered significant attention across social media platforms, short and long-form video platforms, and podcasts, owing to its unique pleasurable and stimulating effects. listen to ASMR for 10mins.
Study NCT06595485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online mindfulness based intervention
Description: We anticipate the online MBI to be 10-20 minutes once daily, at least 5 days per week, for 8 weeks. Online MBI will be available free of charge on iOS and Android platforms. Participants will be instructed to download the app and use for practices. The online MBI group will be introduced to practice including mindful breathing (simple attention to the flow of the breath, inhalations, and exhalations), body scan (attention and awareness of different body parts) and practice of non-judgement of thoughts and emotions and guided meditation (sitting meditation). In addition, we anticipate participants in MBI group will have a group discussion via skype, 30 minute a week for 8 weeks. Moreover, we anticipate participants in MBI group to record how they practice in each day (attendance) as home assignment using online MBI application. For the details of mindfulness practice, we will develop based on data from interview and focus group
Study NCT06599398 — intervention group
Intervention type: OTHER
Intervention: Jeroen Pit Huis
Description: The JPH is a unique and innovative Transitional Care Unit (TCU) situated in close proximity of the AUMC. In this TCU, patients and their family reside in separate private home-like apartments. The families can stay while practising in, and adapting to, their new reality until they are ready to transition home. A multidisciplinary team of healthcare experts (nurses, psychosocial care workers, family counsellors, and paediatricians) are gradually guiding parents towards taking on the role of their child's primary caregiver. This process is guided by a newly developed seven phase care path.One condition for staying in the JPH is that one parent is always present. In this form (24/7 parental stay and nursing care directly available under the supervision of pediatricians) the JPH is unique in the Netherlands.
Study NCT06603740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthrex Nanoscope
Description: Arthrex's all-in-one disposable, 2 mm, chip-on-tip camera system now allows surgeons to miniaturize their treatment solutions
Study NCT06603740 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Arthroscopy without Arthrex Nanoscope
Description: partial meniscectomy using conventional arthroscopy
Study NCT06586099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aza, tislelizumab
Description: combination chemotherapy for the refractory/relapsed AML
Study NCT06595732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor and abdominal training
Description: Participants in this group will undergo 12 weeks of in-person training, with supervision by a specialist physical therapist, in groups of up to four women. The training will take place after an initial evaluation and will consist of 24 sessions, held twice a week. Exercises will target both the pelvic floor muscles and the abdominal muscles. The exercises will be divided into three phases, with progressively increasing difficulty each month. The progression will be achieved by increasing the load, the number of repetitions, and the complexity of the exercises.
Study NCT06595732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal Hypopressive Technique Exercises
Description: Participants in this group will perform Hypopressive Abdominal Gymnastics exercises as proposed by Marcel Caufriez (1997). The training will last 12 weeks and be conducted in person, with supervision by a specialist physical therapist, in groups of up to four women. The training will take place after an initial evaluation and will consist of 24 sessions, held twice a week. The exercises will be divided into three phases, with progressively increasing difficulty each month. Progression will be achieved by changing body positions, increasing the number of repetitions, and extending the duration of inspiratory apnea.
Study NCT06595732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Participants in this group will undergo 12 weeks of in-person training, supervised by a specialist physical therapist, in groups of up to four women. Specific exercises targeting the pelvic floor muscles will be performed, with voluntary and maximal contractions, without involving other muscle groups. The exercises will be divided into three phases, with progressively increasing difficulty each month. Progression will be achieved by increasing the load (transitioning from gravitational to antigravitational positions), increasing the number of repetitions, and combining sustained and rapid contractions to enhance the difficulty of execution.
Study NCT06597253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lactate sensor
Description: Continuous interstitial fluid lactate monitoring using the non-invasive Nemaura Investigational Lactate Device.
Study NCT06588764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified deep lateral and/or medial wall decompression
Description: Modified deep lateral orbital wall decompression is based on traditional outer wall decompression with combined abrasion of the deep outer orbital wall (including the greater pterygoid wing) to achieve adequate enlargement of the orbital cavity.
Study NCT06588621 — intervention group
Intervention type: OTHER
Intervention: Questionnaire on physical and mental health among healthcare professionnals
Description: Feedback on the results of the questionnaire and toolkit on resources with regard to healthy habits in the professional setting